THE COST SAVINGS ASSOCIATED WITH BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BEVACIZUMAB-BASED THERAPY) TREATMENT COMPARED WITH CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CETUXIMAB-BASED THERAPY) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL CANCER (NSCLC) ACROSS FOUR EUROPEAN COUNTRIES

被引：0

作者：

Nuijten, M. ^{[1
]}

Chouaid, C. ^{[2
]}

Vergnenegre, A. ^{[3
]}

机构：

[1] Ars Accessus Med, Jisp, Netherlands

[2] Hop St Antoine, F-75571 Paris, France

[3] CHU Limoges, Limoges, France

来源：

VALUE IN HEALTH | 2009年 / 12卷 / 03期

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A41 / A41

页数：1

共 50 条

[1] COST-SAVINGS ASSOCIATED WITH BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) COMPARED WITH CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY
Heigener, D.
Bischoff, H. G.
Wiesner, C.
Aultman, R.
VALUE IN HEALTH, 2009, 12 (07) : A263 - A264
[2] A cost analysis of treatment with bevacizumab plus cisplatin and gemcitabine (BCG) versus cetuximab plus vinorelbine and cisplatin (CVC) in patients with advanced or recurrent non-small cell lung cancer (NSCLC) in Germany
Heigener, D. F.
Wiesner, C.
Aultman, R.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[3] A cost effectiveness analysis of bevacizumab plus cisplatin and gemcitabine (BCG) versus cetuximab plus vinorelbine and cisplatin (CVC) in patients with advanced or recurrent non-small cell cancer (NSCLC) in Spain
Castro Carpeno, Javier D.
Castro Gomez, Antonio J.
Walzer, Stefan
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S670 - S670
[4] A COST EFFECTIVENESS ANALYSIS DEMONSTRATES THE BENEFITS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN SPAIN
de Castro Carpeno, J.
Castro Gomez, A.
Walzer, S.
VALUE IN HEALTH, 2009, 12 (07) : A273 - A274
[5] An indirect comparison of the efficacy of bevacizumab plus cisplatin and gemcitabine (BCG) or bevacizumab plus carboplatin and paclitaxel (BCP) versus pemetrexed plus cisplatin (PC) and cetuximab plus vinorelbine and cisplatin (CVC) in patients (pts) with advanced or recurrent non-small cell cancer (NSCLC)
Walzer, S.
de Castro Carpeno, J.
Vergnenegre, A. V.
Chouaid, C.
Heigener, D. F. H.
Bischoff, H. G.
Nicolson, M. C.
Aultman, R.
Siebert, U.
EJC SUPPLEMENTS, 2009, 7 (02): : 555 - 555
[6] Analysis of the costs of bevacizumab plus cisplatin and gemcitabine versus cetuximab plus vinorelbine and cisplatin in patients with advanced non-small cell lung cancer (NSCLC) in France: Results from a cost modelling study
Chouaid, C.
Vergnenegre, A.
Florentin, V.
Walzer, S.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[7] AN INDIRECT COMPARISON OF THE EFFICACY OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) OR BEVACIZUMAB PLUS CARBOPLATIN AND PACLITAXEL (BCP) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
Walzer, S.
de Castro Carpeno, J.
Vergnenegre, A.
Chouaid, C.
Heigener, D.
Bischoff, H. G.
Aultman, R.
Siebert, U.
VALUE IN HEALTH, 2009, 12 (07) : A258 - A258
[8] THE BENEFITS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN SWEDEN: RESULTS FROM A COST-EFFECTIVENESS ANALYSIS
Nuijten, M. J.
Holmberg, C.
Walzer, S.
VALUE IN HEALTH, 2009, 12 (07) : A272 - A272
[9] THE COSTS OF TREATING PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL CANCER (NSCLC) WITH BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE COMPARED WITH PEMETREXED PLUS CISPLATIN IN INDUCTION AND MAINTENANCE THERAPY IN GERMANY AND ITALY
Nuijten, M.
VALUE IN HEALTH, 2009, 12 (03) : A41 - A41
[10] Analysis of cost-effectiveness of Bevacizumab plus cisplatin and gemcitabine (BCG) compared to an induction therapy with pemetrexed plus cisplatin (PC) in advanced or recurrent non-small cell lung cancer (NSCLC)
Bischoff, H.
Heigener, D.
Wiesner, C.
Walzer, S.
ONKOLOGIE, 2010, 33 : 131 - 132

← 1 2 3 4 5 →